BRCA2 and prostate carcinoma: Finally, van Asperen et al (2005) in a analysis of 139 BRCA2 families from the Netherlands reported an RR of 2.5 (95%CI 1.6–3.8) for prostate cancer among BRCA2 protein-truncating mutation carriers.